


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 233/54, A61K 31/495 C07D 403/06, A61K 31/55	A1	(11) International Publication Number: WO 93/12093 (43) International Publication Date: 24 June 1993 (24.06.93)
(21) International Application Number: PCT/US92/10697 (22) International Filing Date: 16 December 1992 (16.12.92) (30) Priority data: 07/810,642 18 December 1991 (18.12.91) US (60) Parent Application or Grant (63) Related by Continuation US 07/810,642 (CON) Filed on 18 December 1991 (18.12.91) (71) Applicant (for all designated States except US): SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).		(72) Inventor; and (75) Inventor/Applicant (for US only) : SHIH, Neng-Yang [US/US]; 1 Maple Drive, North Caldwell, NJ 07006 (US). (74) Agents: JEANETTE, Henry, C. et al.; Schering-Plough Corporation, Patent Department, M3W, One Giralda Farms, Madison, NJ 07940-1000 (US). (81) Designated States: AU, BB, BG, BR, CA, CS, FI, HU, JP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: IMIDAZOLYL-ALKYL-PIPERAZINE AND -DIAZEPINE DERIVATIVES AS HISTAMINE H3 AGONISTS/ANTAGONISTS <div style="text-align: center;">  </div> (57) Abstract <p>Disclosed is a compound of formula (1.0) or a pharmaceutically acceptable salt or solvate thereof. Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a compound of formula (1.0). Further disclosed is a method of treating allergy (for example asthma), inflammation, hypertension, raised intraocular pressure (such as glaucoma) - i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypo motility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimers, Schizophrenia, and migraine) comprising administering an effective amount of a compound of Formula (I) to a patient in need of such treatment.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	CN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

5


- 10 Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine H₃ agonists/antagonists

BACKGROUND

- 15 H₃ receptor sites are known and are of current interest to those skilled in the art--for example, see: West, Jr. et al., "Biexponential Kinetics of (R)- α -[³H]Methylhistamine Binding to the Rat Brain H₃ Histamine Receptor", Journal of Neurochemistry, Vol. 55, No. 5, pp. 1612-1616, 1990; West, Jr. et al., "Identification of Two H₃-Histamine
- 20 Receptor Subtypes", Molecular Pharmacology, 38:610-613; and Korte et al., "Characterization and Tissue Distribution of H₃ Histamine Receptors in Guinea Pigs by N α -Methylhistamine", Biochemical and Biophysical Research Communications, Vol. 168, No. 3, pp. 979-986..

Arrang et al. in U.S. 4,767, 778 (Issued August 30, 1988)

- 25 disclose a pharmaceutical composition containing a histamine derivative of the formula:




- 30 wherein each of R₁, R₂, and R₄, represents a hydrogen or a methyl, or R₁ and R₂ taken together represent a methylene, and R₃ is a hydrogen, a methyl or a carboxy, with the proviso that R₁, R₂, R₃, and R₄ are not


- 2 -

simultaneously methyl groups. It is disclosed that the derivatives behave as complete agonists of the H₃ receptors in rat brain and produce a maximal inhibition of release identical to that induced by histamine (approximately 60%). It is also disclosed that the histamine derivatives powerfully inhibit the release and synthesis of histamine by very selectively stimulating the H₃ receptors. Consequently, according to Arrang et al., the derivatives are likely to decrease histaminergic transmission in the digestive tract and in the nervous, cardiovascular and immune systems. Arrang et al. disclose that the derivatives can be used in therapy as a drug having sedative effects, as a sleep regulator, anticonvulsant, regulator of hypothalamo-hypophyseal secretion, antidepressant, and modulator of cerebral circulation. According to Arrang et al., inhibition of the release of inflammation messengers in various allergic conditions (e.g., asthma) is expected to result from stimulation of the H₃ receptors of the lung. It is further disclosed that the inhibition of release of gastric histamine is likely to exert antisecretory and antiulcerative effects. According to Arrang et al., modification of release of the messengers of immune responses is likely to modulate the latter responses.

EP 0 338 939 discloses compounds of the formula:




Derwent abstract 86-273706/42 for EP 0 197 840 discloses imidazole derivatives of the formula:




- 3 -

wherein R_1 is H, methyl or ethyl; R is H or R_2 ; and R_2 is 1-6C alkyl, piperonyl, 3-(benzimidazol-1-yl)propyl, -CZ-NHR₅ or a group (i):



5


wherein n is 0-3; X is a bond, O, S, NH, CO, CH=CH or a group (ii):



- 10 R_3 is H, methyl, halo, CN, CF₃ or COR₄; R_4 is 1-6C alkyl, 3-6C cycloalkyl or phenyl (optionally substituted by methyl or F); Z is O, S, NH, N-methyl or N-CN; and R_5 is 1-8C alkyl, 3-6C cycloalkyl (optionally substituted by phenyl), 3-6C cycloalkyl(1-3C)alkyl, phenyl (optionally substituted by methyl, halo or CF₃), phenyl(1-3C)alkyl, naphthyl, adamantyl or
- 15 p-toluenesulphonyl. It is disclosed that these compounds are psychotropic agents. It is also disclosed that these compounds antagonise the histamine H₃ receptors and increase the speed of cerebral histamine renewal.

Derwent abstract 90-184730/24 for U.S. 4,925,851

- 20 discloses 2- or 4-(2-(1H-imidazol-1-yl)ethyl) piperidine compounds useful as antitumour agents for inhibiting lymphoma, sarcoma, myeloma and leukaemia. The compounds have the formula:




25

wherein R is -CH₂(CH₂)_m-Me, -CO-(CH₂)_m-Me or -CO-CMe₂-R₂; m is 2-18; R_2 is H or Me; R_1 is -(CH₂)_n-R₃; n is 0-13; R_3 is H, i-Pr or t-Bu; and

- 4 -


the floating group is at the 2- or 4- position; with the proviso that (1) the sum of C atoms in R_1 does not exceed 13; and (2) the sum of C atoms in R and R_1 does not exceed 25.

Derwent abstract 90-180087/24 for EP 372125A discloses
5 compounds of the formula:



wherein X is O or S; R_1 is halo, CF_3 , CN, NO_2 , OH, or 1-6C alkoxy; R_2 is
10 H, 1-6C alkyl, aryl, 7-13C aralkyl, optionally substituted amino or 5- or
6-membered N-containing ring; and R_3 is 1-6C hydrocarbyl, 7-13C
aralkyl or 1-13C acyl. It is disclosed that these compounds have α_2 -
antagonist activity with no dopamine activity and that they are useful for
treating depression and other related illnesses (e.g., anxiety or cognitive
15 disorders).

Derwent abstract 88-309195/44 for U.S. 4935417
discloses compounds of the formula:




20

- 5 -


wherein (according to U.S. 4935417) R¹ is aryl, lower alkyl, cycloalkyl or hydrogen; R² is aryl, lower alkyl or hydrogen; R³ is lower alkyl, hydroxy or hydrogen; R⁴ is aryl or hydrogen; R⁵ is aryl or hydrogen; m is two or three; n is zero, one or two, provided that when R³ is hydroxy, n is one or two; and q is zero, one, two or three. U.S. 4935417 discloses that these compounds are calcium channel antagonists useful for treating mammals having a variety of disease states, such as stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism and also for treatment of spinal injuries

10

Compounds known in the art include:




RN 85651-90-7
CA98(23):194919y



RN 81345-39-3
CA96(17):139642m

- 6 -




RN 81345-38-2
CA96(17):139642m

and

Known compounds in the art also include compounds of
the formula:

5



wherein R (Table 1) is:


- 7 -

TABLE 1


NO.	R	RN	CA
1	-CH ₃	106243-44-1	106(11):84602r
2	-CH(CH ₃) ₂	106243-45-2	106(11):84602r
3	H	106243-23-6	106(11):84602r
4	-C(S)NHC(CH ₃) ₂ CH ₂ C(CH ₃)	106243-93-0	106(11):84602r
5	-C(O)NHCH(CH ₃)(phenyl)	106243-90-7	---
6	-C(S)NH(p-chlorophenyl)	106243-85-0	---
7	-C(O)NH(phenyl)	106243-77-0	---
8	-C(NH)N(CH ₃)(cyclopropyl)	106243-73-6	---
9	-C(S)NHCH ₃	106243-61-2	---
10	-CH ₂ CH ₂ -phenyl	106243-49-6	---
11	-CH ₂ CH ₂ -p-fluorophenyl	106243-67-8	---
12	benzyl	106243-25-8	---

Additionally known compounds include:

5







RN 51746-84-0
CA80(15):82801a






RN 67319-35-1
CA89(13):109229v

- 8 -



5

- 9 -



5

In view of the art's interest in compounds which effect the H_3 receptors, novel compounds having agonist or antagonist activity on H_3 receptors would be a welcome contribution to the art. This invention provides just such a contribution by providing novel compounds having H_3 agonist or antagonist activity.


10

SUMMARY OF THE INVENTION

15

This invention provides compounds of the formula:

- 10 -



or a pharmaceutically acceptable salt or solvate thereof, wherein:

- 5 (A) n is 1 or 2, such that when n is 1 then ring T is a six membered ring, and when n is 2 then ring T is a seven membered ring;
- (B) R^1 is selected from the group consisting of:
- 10 (1) H;
- (2) C_1 to C_6 alkyl;
- (3) allyl; and
- (4) propargyl;
- (C) R^3 and R^4 are independently selected from the group consisting of:
- 15 (1) H;
- (2) C_1 to C_6 alkyl;
- (3) allyl;
- (4) propargyl; and
- (5) $-(CH_2)_q-R^5$ wherein q is an integer of: 1 to 7, and R^5 is selected from the group consisting of: phenyl, substituted phenyl, $-OR^6$, $-C(O)OR^6$, $-C(O)R^6$, $-OC(O)R^6$, $-C(O)NR^6R^7$, CN and $-SR^6$ wherein R^6 and R^7 are as defined below, and wherein the substituents on said substituted phenyl are each independently selected from the group consisting of:
- 20 $-OH$, $-O-(C_1 \text{ to } C_6)\text{alkyl}$, halogen, C_1 to C_6 alkyl, $-CF_3$, $-CN$, and $-NO_2$, and wherein said substituted phenyl contains from 1 to 3 substituents;
- 25 (D) R^6 and R^7 are each independently selected from the group consisting of: H and C_1 to C_6 alkyl; and

- 11 -

(E) R^3 and R^4 are each independently bound to the same or different carbon atom of ring T.

Those skilled in the art will appreciate that the total number of substituents on each $-(C)_n-$ is two, and that such substituents are
5 independently selected from the group consisting of H, R^3 , and R^4 , such that there is only one R^3 and one R^4 substituent in ring T.

This invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of Formula 1.0.

10 This invention further provides a method of treating allergy, (for example asthma), inflammation, hypertension, raised intraocular pressure (such as glaucoma)—i.e., a method of lowering intraocular pressure, sleeping disorders (e.g., hypersomnia, somnolence,
15 narcolepsy and sleeplessness, such as insomnia), states of hyper and hypo motility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimers,
20 Schizophrenia, and migraine) comprising administering an effective amount of a compound of Formula I to a patient in need of such treatment.

DETAILED DESCRIPTION OF THE INVENTION

As used herein the following terms have the following
25 meanings unless indicated otherwise:

alkyl - represents a straight or branched, saturated hydrocarbon chain having from 1 to 6 carbon atoms;

cycloalkyl - represents a saturated carbocyclic ring having from 3 to 6 carbon atoms;

30 halogen (halo) - represents fluoro, chloro, bromo or iodo;

DMF - stands for N, N-dimethylformamide;

SEM - stands for 2-(trimethylsilyl)ethoxymethyl; and


THF - stands for tetrahydrofuran.

- 12 -


Also, unless stated otherwise, the substituents for the various embodiments described below are as defined for Formula 1.0.

In the compounds of this invention, preferably R^3 and R^4 are each independently selected from the group consisting of: H, C_1 to C_6 alkyl, allyl, propargyl, and $-(CH_2)_q-R^5$ wherein R^5 is phenyl or substituted phenyl. Most preferably, R^1 , R^3 and R^4 are each independently selected from the group consisting of H and C_1 to C_6 alkyl. More preferably, R^1 , R^3 and R^4 are each independently selected from H and methyl. Preferably, R^1 , R^3 and R^4 are H.

Representative compounds of this invention include compounds of the formula:





; and




15

Representative compounds of Formula 1.0 include:




;

;




; and



20

- 13 -

Representative compounds of Formula 1.0 also include:



5 Certain compounds of the invention may exist in different isomeric (e.g., enantiomers and diastereoisomers) forms. The invention contemplates all such isomers both in pure form and in admixture, including racemic mixtures. Enol forms are also included.

10 The compounds of Formula 1.0 can exist in unsolvated as well as solvated forms, including hydrated forms, e.g., hemi-hydrate. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol and the like are equivalent to the unsolvated forms for purposes of the invention.

15 Certain basic compounds of the invention also form pharmaceutically acceptable salts, e.g., acid addition salts. For example, the nitrogen atoms may form salts with acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well
20 known to those in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner. The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as
25 dilute aqueous sodium hydroxide, potassium carbonate, ammonia and sodium bicarbonate. The free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise equivalent to their respective free base forms for purposes of the invention.

30 All such acid and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and

- 14 -


all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.

- 5 The following processes may be employed to produce compounds of Formula 1.0. Unless stated otherwise, reactions are conducted at an appropriate temperature which allows the reaction to proceed at a reasonable rate to completion.

A PREPARATION OF COMPOUNDS WHEREIN m IS 1

10

SCHEME 1




15

In Step 1 of Scheme 1, compound (1), wherein n is 1 or 2, is reacted with compound (2) at a temperature of about 20 to about 80°C in an organic solvent to produce compound (3). Preferably, ethanol is used as the organic solvent, but other suitable solvents include methanol, propyl alcohol and the like.


- 15 -

In Step 2 of Scheme 1, compound (3) is then dissolved in an aqueous acid to form a salt, compound (4). Examples of aqueous acids include HCl, HBr, H₂SO₄ and the like. Preferably HCl is employed (i.e., in compound (4) HA is HCl). The above reaction is conducted at a temperature of about -20 to about 20°C. Alternatively, compound (3) is reacted with di-*t*-butyl-dicarbonate in an organic solvent (e.g., DMF, CH₂Cl₂ and the like) at a temperature of about 0 to about 50°C, and the reaction product (compound (3) wherein the NH groups of the imidazole and the cyclic amine are protected with -C(O)O(*t*-butyl)) is then reacted with aqueous acid at a temperature of about -20 to about 20°C to produce compound (4).

Compound (2) is prepared in three steps from Compound (5):



15 Z represents the protecting group:



- 16 -

Z can be other groups, such as 2-(trimethylsilyl)ethoxymethyl, benzyloxycarbonyl and the like; however, unless stated otherwise, Z preferably represents the trityl group in the processes as described below for making the compounds of this invention.

5 Those skilled in the art will appreciate that other protecting groups known in the art may be used—such as, for example, base sensitive groups wherein the protected compounds would be deprotected using basic conditions (e.g., NaOH). The processes described herein wherein the protected compound is deprotected under
10 acidic conditions may also be carried out under basic conditions when a base sensitive protecting group is used.


 Compound (5) is reacted with an organometallic reagent R^1M , wherein M is Li or MgBr, to produce compound (6). The reaction takes place in an inert organic solvent at a temperature of about -78 to
15 0°C. Suitable inert organic solvents include: THF, diethyl ether and the like. Compound (6) is then reacted with thionyl chloride in an inert organic solvent such as benzene or CH_2Cl_2 , in the presence of base to generate compound (7). The reaction is conducted at a temperature of about -20 to 80°C. Suitable bases include: pyridine, triethylamine and
20 the like. Preferably, triethylamine is used as the amine base. Compound (7) is then deprotected with dilute aqueous acid, such as HCl or HBr, at a temperature of about 50 to about 90°C to produce compound (2). Other protecting groups are removed by methods known in the art. Compound (5) can be obtained by following the literature
25 procedure set forth in J.K. Kelly, et al., J. Med. Chem, 20, 721(1977).

B. PREPARATION OF COMPOUNDS WHEREIN m IS 1

SCHEME 2

30

- 17 -




In Step 1 of Scheme 2, compound (8) is produced by reacting compound (1) with compound (7) in an inert organic solvent at a temperature of about 20 to about 80°C. Suitable organic solvents include THF, DMF, ethanol and the like. Preferably THF is used as the organic solvent. The reaction can be conducted with or without amine base. Suitable bases include triethylamine and the like. Compound (8) is then deprotected with dilute aqueous acid (HA) at a temperature of about 50 to about 90°C to generate compound (4). Suitable aqueous acids include HCl, HBr, and the like.

C. PREPARATION OF COMPOUNDS WHEREIN *m* IS 1

SCHEME 3

- 18 -




By following the steps in Scheme 2, with the exception that compound (9) (wherein n is 1 or 2, and Y is a protecting group such as trityl, $-\text{CO}_2\text{C}(\text{CH}_3)_3$, or SEM group) is used instead of compound (1), compound (4) is produced.

D. PREPARATION OF COMPOUNDS WHEREIN m IS 1

SCHEME 4


- 19 -




- In Step 1 of Scheme 4, compound (11) is reacted with compound (1), in an inert organic solvent and in the presence of a
- 5 reducing agent, to produce compound (8). The reaction can be conducted at a temperature of about -20 to about 50°C. Methanol is the preferred organic solvent; however, other suitable solvents include ethanol, DMF and the like. Suitable reducing agents include $NaBH_3CN$, $NaBH_4$, and Pd/C . When the latter (Pd/C) is employed as the reducing
- 10 agent, the reaction is conducted under H_2 atmosphere. The conversion of compound (8) to compound (4) is accomplished by following the same procedure described above in Step 2 of Scheme 2.

Compound (1)

- 20 -




may be prepared by:



10 The hydrogenation of compound (12) is carried out using Pd-black as the catalyst, in an organic solvent, e.g., ethanol, methanol, THF and the like, using a temperature of about 20 to about 100°C, under a hydrogen at a pressure of about 1 to about 10 atmospheres.

- 21 -



In Step (1) of (II), compound (13) is reacted with Z-Cl in an organic solvent in the presence of a base to produce compound (14). The reaction is carried out at a temperature of about 0 to about 70°C. Examples of suitable bases include NaH, KH and the like. Suitable solvents include THF, DMF and the like. Z represents trityl or (CH₃)₃CSi(CH₃)₂-.

In Step (2) of (II), the anion of compound (14) is reacted with R³-L in an organic solvent to produce compound (15). The reaction is carried out at a temperature of about -78 to about 50°C. Examples of

- 22 -


solvents include THF, 1,4-dioxane and the like. L represents a leaving group, such as, for example, Cl, Br, I and the like. The anion of compound (14) is generated by reacting compound (14) with a base, such as LDA, KH and the like.

5 In Step (3) of (II), the anion of compound (15) is reacted with R^4-L in an organic solvent to produce compound (16). The reaction is carried out at a temperature of about -78 to about 50°C . Examples of solvents include THF, 1,4-dioxane and the like. L represents a leaving group, such as, for example, Cl, Br, I and the like. The anion of
10 compound (15) is generated by reacting compound (15) with a base, such as LDA, KH and the like.

In Step (4) of (II), compound (16) is reduced with LiAlH_4 to produce compound (17). The reduction takes place in an organic solvent, such as THF, 1,4-dioxane and the like, and at a temperature of
15 about 20 to about 100°C .

In Step (5) of (II), compound (17) is deprotected, to produce compound (1A), using aqueous acid, such as HCl, HBr, HI and the like. The deprotection step is carried out at a temperature of about 25 to about 100°C in an organic solvent, such as 1,2-dichloroethane,
20 ethanol and the like.

- 23 -



In Step (1) of (III), compound (15) is reacted with lawesson's reagent to produce compound (18). The reaction is carried out at a temperature of about 50 to about 120°C in an organic solvent, such as toluene, benzene and the like.

In Step (2) of (III), compound (18) is reacted with R⁴M, wherein M represents Li or the grignard reagent MgX (X represents halogen), which is then followed by reaction with LiAlH₄ to produce compound (1). A similar reaction is described in Tet. Letters, 28, 1529 (87).

In the above processes, it is sometimes desirable and/or necessary to protect certain groups during the reactions. Certain protecting groups are employed in the above processes but, as those skilled in the art will recognize, other protecting groups may be used in their place. Conventional protecting groups are operable as described in Greene, T.W., and Wuts, P.G.M., "Protective Groups In Organic Synthesis," John Wiley & Sons, New York, 1991; the disclosure of which is incorporated herein by reference thereto. After the reaction or

- 24 -

reactions, the protecting groups may be removed by standard procedures.

5 The compounds of this invention are either agonists or antagonists of the histamine H₃ receptor. The binding affinity of the compounds of the invention to the H₃ receptor may be demonstrated by the procedure described below:

H₃ Receptor Binding Assay

10

The source of the H₃ receptors in this experiment was guinea pig brain. The animals used weighed 400-600 g. The tissue was homogenized using a Polytron in a solution of 50 mM Tris, pH 7.5. The final concentration of tissue in the homogenization buffer was 10% w/v. The homogenates were centrifuged at 1000 x g for 10 min. in order to remove clumps of tissue and debris. The resulting supernatants were then centrifuged at 50,000 x g for 20 min. in order to sediment the membranes, which were next washed 3 times in homogenization buffer (50,000 x g for 20 min. each). The membranes were frozen and stored at -70°C until needed.

20

All compounds to be tested were dissolved in DMSO and then diluted into the binding buffer (50 mM Tris, pH 7.5) such that the final concentration was 2 µg/mL with 0.1% DMSO. Membranes were then added (400 µg of protein) to the reaction tubes. The reaction was started by the addition of 3 nM [³H]R-α-methylhistamine (8.8 Ci/mmol) or [³H]-N-methylhistamine (80 Ci/mmol) and incubated at 30° for 30 min. Bound ligand was separated from unbound ligand by filtration, and the amount of radioactive ligand bound to the membranes was quantitated by liquid scintillation spectrometry. All incubations were performed in duplicate and the standard error was less than 10% in all instances. Compounds that inhibited greater than 70% of the specific binding of radioactive ligand to the receptor were serially diluted to determine a K_i (µM). The results are given in Table 2.

25






30

- 25 -

In Table 2, the compound represented by (a*) is known in the art.

TABLE 2

5

COMPOUND	H ₃ Binding K _i (μM)
 <chem>NCCc1c[nH]cn1</chem> • 2HCl (a*)	0.014
 <chem>C1CCN(C1)Cc2c[nH]cn2</chem> • 3HCl	0.0047
 <chem>C[C@H]1CCN(C1Cc2c[nH]cn2)C</chem> • 3HCl	6%
 <chem>C[C@@H]1CCN(C1Cc2c[nH]cn2)C</chem> • 3HCl	24%
 <chem>C1CCN(C1)Cc2c[nH]cn2</chem> • 3HCl	0.087

For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically

- 26 -

acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 70 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar, lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.

Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection.

Liquid form preparations may also include solutions for intranasal administration.

Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.

Preferably the compound is administered orally.

Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.

- 27 -


The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, more preferably from about 1 mg to 500 mg, according to the particular application.

5 The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the
10 compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

15 The amount and frequency of administration of the compounds of the invention and the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended dosage regimen is oral administration of from 1 mg to
20 2000 mg/day preferably 10 to 1000 mg/day, in one to four divided doses to achieve relief of the symptoms. The compounds are non-toxic when administered within this dosage range.

25 The invention disclosed herein is exemplified by the following examples, which should not be construed to limit the scope of the disclosure. Alternative mechanistic pathways and analogous structures within the scope of the invention may be apparent to those skilled in the art.

- 28 -


EXAMPLE 1

5


To a refluxing solution of 8.6 g of piperidine in 50 mL of absolute ethanol was added a solution of 1.53 g of 4-chloromethylimidazole hydrochloride (1) in 10 mL of absolute ethanol for over 1.5 hr. After an additional 2 hours of refluxing, the reaction mixture was cooled and the ethanol and excess piperidine were removed by vacuum distillation. The residue (2) was used directly in Step B (below).

10

- 29 -



To a mixture of the residue **2** in 70 mL of anhydrous DMF
 5 was added 19 mL of triethylamine and 21 mL of di-*t*-butyl-dicarbonate at
 room temperature under nitrogen. The resulting mixture was stirred for
 29 hours, and then it was filtered. The filtrate was concentrated under
 vacuum and the residue was purified by flash chromatography on silica
 gel to give 1.73 g of the compound of formula **3** (50% yield from **1**),
 10 which was recrystallized in ethyl acetate. MS (FAB) 367 ($\text{M}+1$).









15 A stirring solution of 1.2 g of compound of formula **3** in 20
 mL of ethyl acetate was cooled to 0°C, and dry HCl gas was bubbled in

- 30 -

for 1 hour. The solid precipitate that resulted was filtered and recrystallized in methanol to give 0.75 g of the compound of formula 4 (80 % yield). MS (EI) 166 (M^+).


- Following the procedure described above in Steps A to C of Example 1, and using the starting compounds set forth in Table 3, compounds 5 to 7 were prepared.

TABLE 3

STARTING COMPOUND	PRODUCT	MS (m/z)
	 <u>5</u>	(EI) 180 (M^+)
	 <u>6</u>	(CI) 195 ($M+1$)
	 <u>7</u>	(CI) 195 ($M+1$)

- 31 -

The following are examples of pharmaceutical dosage forms which contain a compound of the invention. As used therein, the term "active compound" is used to designate the compound



The scope of the invention in its pharmaceutical composition aspect is not to be limited by the examples provided, since any other compound of structural formula 1.0 can be substituted into the pharmaceutical composition examples.

Pharmaceutical Dosage Form Examples

EXAMPLE A Tablets

<u>No.</u>	<u>Ingredients</u>	<u>mg/tablet</u>	<u>mg/tablet</u>
1.	Active compound	100	500
2.	Lactose USP	122	113
3.	Corn Starch, Food Grade, as a 10% paste in Purified Water	30	40
4.	Corn Starch, Food Grade	45	40
5.	Magnesium Stearate	<u>3</u>	<u>7</u>
	Total	300	700

Method of Manufacture

Mix Item Nos. 1 and 2 in a suitable mixer for 10-15 minutes. Granulate the mixture with Item No. 3. Mill the damp granules

- 32 -

through a coarse screen (e.g., 1/4", 0.63 cm) if necessary. Dry the damp granules. Screen the dried granules if necessary and mix with Item No. 4 and mix for 10-15 minutes. Add Item No. 5 and mix for 1-3 minutes. Compress the mixture to appropriate size and weigh on a suitable tablet machine.

EXAMPLE B
Capsules

No.	Ingredient	mg/capsule	mg/capsule
1.	Active compound	100	500
2.	Lactose USP	106	123
3.	Corn Starch, Food Grade	40	70
4.	Magnesium Stearate NF	<u>4</u>	<u>7</u>
	Total	250	700

Method of Manufacture


Mix Item Nos. 1, 2 and 3 in a suitable blender for 10-15 minutes. Add Item No. 4 and mix for 1-3 minutes. Fill the mixture into suitable two-piece hard gelatin capsules on a suitable encapsulating machine.

While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

- 33 -

WHAT IS CLAIMED IS:

1. A compound of the formula:



or a pharmaceutically acceptable salt or solvate thereof, wherein:

- (A) n is 1 or 2, such that when n is 1 then ring T is a six membered ring, and when n is 2 then ring T is a seven membered ring;
- (B) R^1 is selected from the group consisting of:
- (1) H;
 - (2) C_1 to C_6 alkyl;
 - (3) allyl; and
 - (4) propargyl;
- (C) R^3 and R^4 are independently selected from the group consisting of:
- (1) H;
 - (2) C_1 to C_6 alkyl;
 - (3) allyl;
 - (4) propargyl; and
 - (5) $-(CH_2)_q-R^5$ wherein q is an integer of: 1 to 7, and R^5 is selected from the group consisting of: phenyl, substituted phenyl, $-OR^6$, $-C(O)OR^6$, $-C(O)R^6$, $-OC(O)R^6$, $-C(O)NR^6R^7$, CN and $-SR^6$ wherein R^6 and R^7 are as defined below, and wherein the substituents on said substituted phenyl are each independently selected from the group consisting of: $-OH$, $-O-(C_1 \text{ to } C_6)\text{alkyl}$, halogen, C_1 to C_6 alkyl,

- 34 -

-CF₃, -CN, and -NO₂, and wherein said substituted phenyl contains from 1 to 3 substituents;

(D) R⁶ and R⁷ are each independently selected from the group consisting of: H and C₁ to C₆ alkyl; and

5 (E) R³ and R⁴ are each independently bound to the same or different carbon atom of ring T.


10 2. The compound of Claim 1 wherein R³ and R⁴ are each independently selected from the group consisting of: H, C₁ to C₆ alkyl, allyl, propargyl, and -(CH₂)_q-R⁵ wherein R⁵ is phenyl or substituted phenyl.

15 3. The compound of Claim 1 wherein R¹, R³ and R⁴ are each independently selected from the group consisting of H and C₁ to C₆ alkyl.

20 4. The compound of Claim 3 wherein R¹, R³ and R⁴ are each independently selected from H and methyl.

5. The compound of Claim 1 wherein n is 1.

25 6. The compound of Claim 1 wherein said compound is selected from the group consisting of compounds having the formula:



wherein R¹ and R³ are as defined in Claim 1.


- 35 -

7. The compound of Claim 6 wherein R¹ and R³ are each independently selected from the group consisting essentially of: H, and C₁ to C₆ alkyl.

5 8. The compound of Claim 7 wherein R¹ and R³ are each independently selected from H and methyl.

9. The compound of Claim 1 wherein said compound is selected from the group consisting of compounds having the formula:

10



wherein R¹ and R³ are as defined in Claim 1.

15

10. The compound of Claim 9 wherein R¹ and R³ are each independently selected from the group consisting essentially of: H, and C₁ to C₆ alkyl.


20

11. The compound of Claim 10 wherein R¹ and R³ are each independently selected from H and methyl.

12. The compound of Claim 1 wherein said compound is selected from the group consisting of compounds having the formula:


25

- 36 -




5

13. A compound having the formula:



10

14. A compound having the formula:



15. A pharmaceutical composition, for use in treating allergy, inflammation, hypertension, glaucoma, sleeping disorders, states of hyper and hypo motility of the gastrointestinal tract, hypo and hyperactivity of the central nervous system, Alzheimers, Schizophrenia, and migraines, comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of Claim 1.

- 37 -

16. A method of treating allergy, inflammation, hypertension, glaucoma, sleeping disorders, states of hyper and hypo motility of the gastrointestinal tract, hypo and hyperactivity of the central nervous system, Alzheimers, Schizophrenia, and migraines comprising administering an effective amount of a compound of Claim 1 to a patient in need of such treatment.

17. The use of a compound of Claim 1 for the manufacture of a medicament for use in treating allergy, inflammation, hypertension, glaucoma, sleeping disorders, states of hyper and hypo motility of the gastrointestinal tract, hypo and hyperactivity of the central nervous system, Alzheimers, Schizophrenia, and migraines.


18. The use of a compound of Claim 1 for the treatment of allergy, inflammation, hypertension, glaucoma, sleeping disorders, states of hyper and hypo motility of the gastrointestinal tract, hypo and hyperactivity of the central nervous system, Alzheimers, Schizophrenia, and migraines.

19. A method of preparing a pharmaceutical composition comprising admixing a compound of Claim 1 with a pharmaceutically acceptable carrier.

20. A process for preparing compounds of Claim 1 comprising:

(A) Scheme 1

- 38 -




1) reacting compound (1) with compound (2) at a temperature of about 20 to about 80°C in an organic solvent to produce compound (3); and

2) (a) dissolving compound (3) in an aqueous acid to form compound (4), the reaction being conducted at a temperature of about -20 to about 20°C; or

(b) reacting compound (3) with di-*t*-butyl-dicarbonate in an organic solvent at a temperature of about 0 to about 50°C, and then reacting the reaction product with an aqueous acid at a temperature of about -20 to about 20°C to produce compound (4);

- 39 -

(B) Scheme 2




- 5 1) reacting compound (1) with compound (7) in an inert organic solvent at a temperature of about 20 to about 80°C to produce compound (8); and
- 2) deprotecting compound (8) with dilute aqueous acid at a temperature of about 50 to about 90°C to generate compound (4);

10

- 40 -


(C) Scheme 3



- 5 1) reacting compound (9), wherein Y is a protecting group, with compound (7) in an inert organic solvent at a temperature of about 20 to about 80°C to produce compound (10); and
- 2) deprotecting compound (10) with dilute aqueous acid at a temperature of about 50 to about 90°C to generate compound
- 10 (4); or

- 41 -

(D) Scheme 4



- 5 1) reacting compound (11) with compound (1) in an inert organic solvent and in the presence of a reducing agent, at a temperature of about -20 to about 50°C, to produce compound (8); and
- 2) deprotecting compound (8) with dilute aqueous acid at a temperature of about 50 to about 90°C to produce compound (4).

10

INTERNATIONAL SEARCH REPORT

PCT/US 92/10697

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 C07D233/54; A61K31/495; C07D403/06; A61K31/55		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07D ; A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	US,A,4 767 778 (J.M. ARRANG ET AL.) 30 August 1988 cited in the application see the whole document & EP,A,0 214 058 (INSERM) ---	1, 15-19
A	WO,A,9 117 146 (INSERM) 14 November 1991 see the whole document ---	1, 15-19
A	EP,A,0 338 939 (INSERM) 25 October 1989 cited in the application see the whole document ---	1, 15-19
A	EP,A,0 197 840 (INSERM) 15 October 1986 cited in the application ---	1, 15-19
-/--		
¹⁰ Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 05 MARCH 1993		Date of Mailing of this International Search Report 17. 03. 93
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer DE JONG B.S.

Form PCT/ISA/210 (second sheet) (January 1985)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	EP,A,0 289 227 (SYNTEX PHARMACEUTICALS) 2 November 1988 see the whole document & US,A,4 935 417 cited in the application -----	1,15-19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/10697

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
"Remark: Although claims 16 and 18 are directed to a method of treatment of
(diagnostic method practised on) the human/animal body the search has been
carried out and based on the alleged effects of the compound/composition."
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9210697
SA 68034

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 05/03/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4767778	30-08-88	FR-A- 2586562	06-03-87
		DE-A- 3685170	11-06-92
		EP-A, B 0214058	11-03-87
		JP-A- 62123174	04-06-87
WO-A-9117146	14-11-91	FR-A- 2661909	15-11-91
		CA-A- 2063550	10-11-91
		EP-A- 0482183	29-04-92
EP-A-0338939	25-10-89	FR-A- 2630328	27-10-89
		JP-A- 3007264	14-01-91
		US-A- 5034539	23-07-91
EP-A-0197840	15-10-86	FR-A- 2579596	03-10-86
		JP-A- 61267574	27-11-86
		US-A- 4707487	17-11-87
EP-A-0289227	02-11-88	US-A- 4829065	09-05-89
		AU-B- 614282	29-08-91
		AU-A- 1510288	27-10-88
		DE-A- 3869821	14-05-92
		JP-A- 63280081	17-11-88
		US-A- 5043447	27-08-91
		US-A- 4935417	19-06-90
		US-A- 5010075	23-04-91
		US-A- 5091428	25-02-92

EPO FORM P077

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82